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Abbreviations 
 
3’ 3 prime 
5’ 5 prime 
APC Antigen presenting cell 
B7 CD80/CD86 Cluster determinant 
Bp base pair 
CD28 Cluster determinant 
CLT Canine lymphocytic thyroiditis 
CTLA-4 Cytotoxic T-lymphocyte antigen 4 
DNA deoxy-ribonucleic acid 
DLA Dog leukocyte antigen 
HT Hashimoto’s thyroiditis 
IgG immunoglobulin G  
MHC Major Histocompatibility complex 
NCBI National Center for bioinformatics 
QTL  quantitative trait loci 
SKC  Swedish Kennel Club 
SLE Systemic Lupus erythomatosus 
SNP Single nucleotide polymorphism 
T4 Thyroxine 
TCR T cell receptor 
TNF-α tumour necrosis factor alpha  
TPO Thyroid peroxidase 
TSH Thyroid stimulating hormone 
TgAA Thyroglobulin auto-antibody 
UCSC University of California at Santa Cruz 
UTR Untranslated region 
WICGR  Whitehead Institute/MIT Center for Genome Research 
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Abstract 
 
The overall aim with this project is to apply a candidate gene approach to identify genes 
predisposing for the autoimmune disease, canine lymphocytic thyroiditis (CLT). Individuals 
clinically diagnosed either as CLT-affected or as healthy non-affected controls were analyzed 
from two birth cohorts of the breeds Giant Schnauzer and Hovawart, breeds that both has  
high incidence of CLT.   
 
Two different genes were evaluated for their potential involvement in CLT disease aetiology. 
Selection of the candidate genes was based on their confirmed role in both human and mouse 
as genetic risk factors in thyroid autoimmune disease. Firstly, to evaluate whether certain 
DLA-DRB1 Major Histocompatibility complex (MHC) class II exon 2 genotypes predispose 
for the development of CLT, cloning and sequencing of DLA-DRB1 exon 2 PCR products 
were performed. Secondly, studies of the gene encoding cytotoxic T-lymphocyte antigen 4 
(CTLA-4) were performed using single nucleotide polymorphism (SNP) analysis and 
microsatellites. Nucleotide sequence analysis of the cloned DLA-DRB1 alleles will allow us to 
evaluate whether certain DRB1 alleles are predisposing for CLT [4]. A microsatellite analysis 
of CTLA-4 strongly suggested that CTLA-4 may be excluded as a gene predisposing for CLT 
in Giant schnauzer, with a chi-square value of 1.96 with three degrees of freedom. For a Chi 
square to be significant for three degrees of freedom it should be greater than or equal to 7.82. 
The P-value was 0.58, which indicates no statistical significance in the results. However, 
additional CLT-affected individuals and healthy controls must be analysed to obtain 
conclusive results.  
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Introduction 
 
Autoimmune disease is common in the dog (Canis familiaris) resulting in substantial 
suffering for the affected dog and high veterinary costs. Some autoimmune diseases such as 
LT are common in both human and dogs, autoimmune diseases therefore constitute excellent 
comparative models for the corresponding human disease, in particular since human and dogs 
often share many environmental factors that affect multifactorial disorders [24].   
 
 
Autoimmune disease 
The results of defects in one or more components of the complex immune cascade that 
operates to establish tolerance to self-antigens and that is required for the defence against 
pathogenic foreign antigens from the body may lead to autoimmune diseases. Autoimmunity 
is characterized by immune reactions directed towards self-antigens and may be associated 
with failure to establish tolerance during thymic education of T lymphocytes or by breaking 
already established tolerance. The outcome of this process is an immune response directed 
towards self antigens and a resulting attack of one or more organs by the immune system [5]. 
The immune system recognizes self-antigens during the development of the immune system 
in the thymus. This thymic education is a complex process that is only partly understood. It 
involves the removal of T cells by negative selection through programmed cell death of T 
cells that express T cell receptors with specificity for self antigens. T cells with intermediate 
and low affinity to self antigens are positively selected to survive to ensure a sufficient 
capacity of the individual to mount immune responses to foreign antigens. This process 
establishes tolerance. Disturbances in these complex pathways could result in the presence of 
auto-reactive T cells with affinity for self-antigens in the periphery. The establishment of 
central tolerance occurs in the thymus and thus, involves both positive and negative selection 
of T cells [18].  
 
Autoimmune disease is common in many species and cells from many different organs can be 
affected in some of these diseases i.e. systemic autoimmune disease such as systemic lupus 
erythematosus (SLE) or a specific cell type in diseases such as autoimmune thyroiditis or 
autoimmune type 1 diabetes [18]. The aetiology of autoimmune disorders is largely unknown 
but is thought to be the result from complex interactions between genetic and environmental 
factors. Some environmental factors that trigger these diseases have been defined and include 
body stress such as diet and infections. The contribution of environmental factors is only 
poorly understood and little evidence for their involvement in disease is found. The genetic 
factors in autoimmune disease have instead strong evidence with increased concordance rates 
seen in monozygotic twins in comparison with dizygotic twins, also individual diseases 
cluster within families. Another indication of genetic influence is that multiple autoimmune 
diseases also cluster within families which strongly suggest that individuals predisposed to a 
particular autoimmune disease share a common genetic background. The predisposal to 
disease may be the outcome of a combination of both general and specific genes [5, 18].  
 
Genetic association studies in human populations have convincingly shown two gene regions 
to be strongly associated with autoimmunity in general and those are particular haplotypes of 
the Major Histocompatibility complex (MHC) class II, in humans called human leukocyte 
antigen (HLA), and the gene encoding cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is a 
regulatory gene in the immune system. These loci encode molecules that are important in the 
immune system and they are actively involved in antigen presentation and T-cell activation 
[5]. Other immune and immune regulatory genes are also probably involved.  
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Hashimoto’s thyroiditis  
Hashimoto's thyroiditis (HT) is one of the most common human autoimmune diseases. It is an 
organ-specific T cell-mediated disease that affects the thyroid gland and genetics play a 
contributory role in its complexity. The disease HT is defined by the dramatic loss of thyroid 
follicular cells, hypothyroidism, goiter and circulation of autoantibodies against two primary 
antigens, thyroglobulin (Tg) and thyroid peroxidase (TPO).  
 
A central phase of HT is characterized by the recognition of presented auto-antigens by T 
lymphocytes, followed by a consistent uncontrolled production of auto-reactive T cells and 
immunoglobulin G (IgG) autoantibodies. Autoimmune responses against thyroid-specific 
antigens are primary determinants in thyroid autoimmunity. Thyroglobulin (Tg) is the main 
protein synthesized in the thyroid gland and serves both in the synthesis and in the storage of 
thyroid hormones. Tg is one of the major auto-antigens in the thyroid and Tg-antibodies are 
detected in almost all patients with HT [7]. Thyroid peroxidase (TPO) is another significant 
autoantigen in patients affected with HT. TPO is an enzyme that catalyses the oxidation of 
iodine that forms iodotyrosines in a Tg molecule. [4] As any disease of a regulatory system 
the problem could lie in the signalling pathway, signal production, signal transmission, signal 
reception or the effectors response downstream. Some examples are genes involved in 
apoptosis such as “death ligands”, Fas and tumour necrosis factor alpha (TNF-α), important 
immune-regulatory proteins, cytokines, and many other genes crucial for a functional immune 
response [7]. 
 
 
Canine Lymphocytic thyroiditis 
Autoimmune canine lymphocytic thyroiditis (CLT) is a complex disease caused by unknown 
predisposing genetic and environmental factors. CLT is considered by veterinary clinicians to 
be analogous to the human disease, Hashimoto’s disease, and has a common aetiology with 
hypothyroidism. However, future clinical, physiological and immunological studies are 
required to formally establish that these diseases are homologous. Most likely, HT has a more 
diverse aetiology compared with CLT. The CLT disease is characterized by insufficient 
production of thyroxine (T4) in the thyroid gland. Thyroid stimulating hormone (TSH) 
stimulates the secretion of T4. The T4 then work with a negative feedback on the pituitary 
gland and down-regulate TSH production. If T4 is not produced because of hypothyroidism, 
the TSH levels do not decrease as in a normal healthy individual.  
 
CLT is one of the most common endochrinopathies in dogs affecting several purebred breeds 
[14]. The disease is most common in dogs between the age of 4 and 10 years and certain 
breeds seem to be predisposed for the disease, such as the breeds Hovawart and Giant 
schnauzer both having approximately 13% incidence proportion in the Swedish populations 
[11].  
 
Autoimmune thyroid diseases are characterized by circulating auto-antibodies to antigens 
expressed by the thyroid gland, activated auto-reactive T cells and lymphocytic infiltration of 
the thyroid gland. In canine lymphocytic thyroiditis there are high concentrations of TSH and 
detectable amounts of circulating autoantibodies. In dog the principal circulating 
autoantibodies are directed against thyroglobulin and are denoted TgAA [25].  
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Dog as an model organism for autoimmune disease  
The complete dog genome nucleotide sequence is now available [37]. The sequencing effort 
was performed by the Broad Institute at MIT and Harvard University; formerly the Whitehead 
Institute/MIT Center for Genome Research (WICGR), a female boxer called Tasha was 
selected as the individual for sequencing because Boxer is one of the breeds with the least 
variation in its genome. Boxer has very low haplotype polymorphism and the nucleotide 
sequences generated are more efficiently annotated. This makes it easier to produce a correct 
genomic nucleotide sequence.   
 
The unique breeding history of the domestic dog provides an unparalleled opportunity to 
explore the genetic basis of disease susceptibility, morphological variation and behavioral 
traits. The position of the dog within the mammalian evolutionary tree also makes the dog 
genome sequence an important resource for comparative analysis of the human genome. Dogs 
evolved through a mutually beneficial relationship with humans, sharing living space and 
food sources [21]. Canine population genetics will be used as a tool to identify quantitative 
trait loci (QTL) and identify the genes underlying important complex traits. Purebred dogs are 
providing information about morphology, behavior and complex diseases, both of themselves 
and humans, by supplying tractable populations in which responsible genes can be mapped. 
The diversification of dog breeds has led to the development of breeds enriched for particular 
genetic disorders. Nearly half of genetic diseases reported in dogs occur predominantly or 
exclusively in one or a few breeds [29]. The high prevalence of specific diseases within 
certain breeds suggests that a limited number of loci underlie each disease, making their 
genetic dissection potentially more tractable in dogs than in humans. This offers an enormous 
advantage in the search for genes associated with complex diseases, which, in theory, can be 
more easily mapped using dog families than human families. [29]  
 
 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene encodes a protein that negatively 
regulates T cells [5]. Mutations in the CTLA-4 gene have been documented as contributing to 
the development of several autoimmune diseases. Thus, the CTLA-4 gene is a major 
autoimmune disease risk factor in general and variations in the gene also play a significant 
role in determining susceptibility to autoimmune thyroid disease in various species [1-3, 5-10, 
15, 21- 23, 27, 30- 31].  
 
The canine CTLA-4 gene is located on dog Chromosome 37 (Cfa 37) and spans approximately 
6.1 kbp and contains four short exons.  
 
 
 
Figure 1. The CTLA-4 gene in dog. 4 exons. Picture adapted from reference [38]. 
 
T cells are activated when the first signal is provided by the interaction of the T cell receptor 
(TCR) on the lymphocyte with major histocompatibility class (MHC) antigens on the antigen-
presenting cell (APC). The second, co-stimulatory, signal is required to avoid an apoptotic or 
anergic response by the lymphocyte. The interaction of CD28 on the lymphocyte with B7 
proteins on the APC provides this necessary co-stimulatory second activation signal. 
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The co-stimulatory molecule that the CTLA-4 gene encodes suppresses T cell-mediated 
immune response and is crucial in the maintenance of self-tolerance. The gene was therefore 
early recognized as a good candidate gene for autoimmune thyroid disease because of its 
importance in T cell regulation. CTLA-4 is a receptor, homologous to CD28, but with 
opposite inhibitory function. The gene belongs to the same family of cell-surface molecules as 
CD28 and like CD28 it binds to B7. The CTLA-4/ B7 complex competes with the CD28/ B7 
complex and delivers negative signals to the T cell and effects T cell expansion, cytokine 
production and immune response [1].  
 
The B7–CD28/CTLA-4 pathway consists of two B7 family members, B7.1 and B7.2, which 
bind to the same two receptors, CD28 and CTLA-4. These two receptors have different 
affinities for B7.1 and B7.2; CD28 is constitutively expressed on the surface of T cells 
whereas CTLA-4 expression is rapidly up-regulated following T cell activation and has higher 
affinity for the B7 receptors. The outcome of an immune response involves a balance between 
CD28-mediated T cell activation and CTLA-4-mediated inhibition [12]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CTLA-4 binds to the B7 receptor and down regulates T cell response.  
 
The importance of CTLA-4 in the down regulation of T-cell response and the induction of 
anergy and tolerance to alloantigens, tumour antigens and pathogens, has been clearly 
demonstrated in experiments with CTLA-4-deficient mice [33]. The exact mechanism how 
CTLA-4 maintains breakdown of self-tolerance that subsequently leads to the initiation of 
autoimmune responses has also been demonstrated in murine models of autoimmune diabetes 
and thyroiditis [7].  The mechanism by which CTLA-4 down-modulates T cell responses is not 
yet clearly defined but several mechanisms have been suggested. CTLA-4 might successfully 
compete with CD28 for its B7 ligands and thereby inhibit the co-stimulatory effect of CD28. 
Alternatively, CTLA-4 might apply its inhibitory effect by acting on downstream signaling 
pathways at activation [5]. Any or all of these hypothesized mechanisms involving CTLA-4 
could contribute to the development of autoimmunity.  
 
The human CTLA-4 gene is known to contain genetic polymorphism in three regions; a single 
base substitution in the promoter, a dimorphism in exon 1 and an multi-allelic di-nucleotide 
repeat in the 3’-UTR of exon 4 [23]. After studies of CTLA-4 it was suggested that 
polymorphisms within the gene are associated with the development in Hashimoto’s disease 
[8]. Further functional studies of CTLA-4 are required to obtain definitive answers as to how 
it affects the autoimmune disease process and if other molecules with similar function as 
negative regulators of T-cell activation might also play a role [5]. 
 
 
 
 
 
T
APC 
MCH class II 
Antigen 
TCR 
B7 
CTLA4 
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DLA-DRB1  
The canine MHC class II region is located on dog chromosome 12 (Cfa 12). The MHC is as 
mentioned above a genetic region that encodes several class II molecules that are strongly 
associated with multiple autoimmune disorders in both dog, human and mouse. The MHC 
genotype is thus far the strongest genetic risk factor for the development of autoimmune 
disease in both human and mouse. 
 
All higher animal species examined so far have within their genome a MHC, a region of 
tightly linked genes largely responsible for the presentation of self and non-self antigens T 
cells of the immune system. The dog MHC is referred to as the dog leukocyte antigen (DLA) 
system [17]. In the present study we have analyzed one class II gene denoted DLA-DRB1. In 
the dog, unlike the human class II region, which exhibits haplotype polymorphism in addition 
to allelic polymorphism, a single DRB locus with extensive allelic polymorphism is present in 
most if not all haplotypes [32]. The fact that the DRB1 locus in all mammals are in strong 
linkage disequilibrium with other polymorphic class II genes e.g. DQB1, allows investigators 
to deduce that individuals expressing a particular DRB1 allele also carries a particular DQB1 
allele on the same chromosome.  
 
The association of MHC genotype with autoimmune disease is quite expected because 
autoimmune responses involve T cells and the ability of T cells to react with specific antigens 
that are presented in the context of MHC class II molecules. Allelic variants of MHC class II 
molecules determine differences in the ability to present auto-antigens to auto-reactive T cells. 
[17].  
 
Alleles and haplotypes of the MHC class II regions have been consistently shown to confer 
either predisposition or protection to many autoimmune diseases. In particular, the human 
HLA-DQB1 locus but also the DRB1 locus has been shown to predispose to autoimmune 
disease. Both DRB1 and DQB1 loci are highly polymorphic with more than 400 human DRB1 
alleles and some 60 DQB1 alleles reported [40]. Also in dogs, both these loci are polymorphic 
and currently 52 DLA-DRB1 alleles have been identified [40]. (See Appendix 1 with all the 
52 different alleles of DLA-DRB1 Figure adapted from reference [40]. The region shown is 
exon 2 which is highly polymorphic and is known to encode a domain that is responsible for 
antigen presentation. There are three hypervariable regions that fold into the peptide-binding 
groove).  
 
The DRB1 peptide-binding domain appears to play a key role in susceptibility to various 
autoimmune diseases. However, MHC class II molecules alone are insufficient to initiate a T-
cell response to antigen, and the presence of co-stimulatory molecules such as CD28 and 
CTLA-4 (see discussion above) is a requirement for positive and negative regulation of T-cell 
proliferation, respectively [5]. 
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Figure 3. Schematic structure of a MHC class II molecule.  
 
 
Microsatellites 
Microsatellites are defined as simple sequence repeats with repeat length up to five bases. The 
most common classes used in genotyping are di-, tri- and tetra nucleotide repeats, witch 
occurs at a rate of about one every 10 kb in eukaryotic genomes [11]. Microsatellites may 
arise by different mechanisms and probably the most common is replication slippage. Once 
established, unequal replication between repeats can generate stepwise changes in repeat 
number. Microsatellites have a much higher mutation rate than non-repetitive sequences and 
they are therefore extremely useful in estimating evolutionary relationship between 
populations within species, but generally evolve too rapidly to be phylogenetically 
informative between species. The simple sequence repeats are important in genetic studies 
both as markers and for pedigree analysis.  The repeats usually occur in non-coding part of 
the genome, and their number is highly variable [11]. 
 
 
Characterization of PCR product  
The PCR products obtained was ligated into the TOPO TA cloning vector (TOPO TA cloning 
kit, InvitrogenTM). The cloning strategy is for direct insertion of Taq Polymerase-amplified 
PCR products into a plasmid vector. The vector is supplied linear with a single 3´-Thymidin 
(T) overhang and topoisomerase covalently bound to the vector, which makes an “active 
vector”. Taq polymerase has a non-template-dependent terminal transferase activity that adds 
a single deoxyadenosine (A) to the 3´-ends of PCR products. The linearized vector supplied 
with in the kits has a single, overhanging 3´-deoxythymidine (T) residue. This allows PCR 
inserts to ligate efficiently with the vector. The recombinant vector is then transformed 
chemically into competent cells of E.coli.  
 
The TOPO TA vector contains the gene LacZα gene which, on plates containing X-gal, 
produces a blue substrate. When vectors contain PCR fragments the LacZα gene is destroyed 
and no blue substrate is produced [15]. 
 
 
α chain   β chain 
COOH COOH 
Peptide-binding site 
-S-S- -S-S- 
| 
S
| 
S
|
| 
S
| 
S
|
H2N 
Plasma 
membrane 
EXTRACELLULAR 
SPACE 
CYTOSOL 
1α
2α
1β
2β
NH2 
 9
 
 
Figure 4. Map of pCR®2.1-TOPO® Vector 3.9 kb. LacZα gene, restriction- and Primer sites. 
Picture adapted from reference [15]. 
 
 
Material and methods 
 
Bioinformatics studies 
The sequence from CTLA-4 gene was retrieved from NCBI and Ensembl genome browser 
[41, 38]. To ensure that the promoter sequence of CTLA-4 was included in the analysis a 
region spanning 1 kb 5’ of the defined transcriptional start site was chosen to design of the 
PCR primers. Promoters can be analyzed in the program found on rVista 2.0 [43]. To find 
SNPs a database called Dog SNPs from Broad Institute was used [37]. 
 
The microsatellite used was a tetra nucleotide repeat found on the dog UCSC genome browser 
[45] and verified manually in the genome sequence found on Ensembl genome browser [38].  
 
 
Study material 
Samples from the two high-risk breeds defined above are available (Giant Schnauzer and 
Hovawart) indicated by epidemiological data accessed and evaluated from databases 
maintained by Agria Insurance company. The clinical diagnostic procedures involve 
measurement of thyroxine (T4), thyroid stimulating hormone (TSH) and autoantibodies 
against thyroglobulin (TgAA) in dogs suspected of suffering from CLT. TSH levels above 
40mlU/L and TgAA antibody concentration are used as inclusion criteria. The concentration 
of TgAA is determined by arbitrary ELISA units and dogs with TgAA above 200% of the 
negative control are considered to be CLT-positive [25]. Case selection is made through 
cooperation with veterinary clinics by screening for inclusion criteria mentioned before. 
Control selection is done by access of the study populations recorded in registries at the 
Swedish Kennel Club (SKC) and Agria insurance company using same criteria for exclusion. 
The validation of control status is done by veterinary examination and owner questionnaires. 
The DLA-DRB1 sequence is investigated in samples from animals in the two birth cohorts [4]. 
The CTLA-4 gene is examined in cases and controls from Giant schnauzer.  
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Extraction of genomic DNA 
Genomic DNA was extracted from 200µl of heparinised blood with modified standard 
procedures. Concentration and quality of the DNA was measured in NanoDrop® ND-1000 
spectophotometer 3.1.0 (Saveen Werner). 
 
 
PCR amplification 
All primers for CTLA-4 were designed using the program Primer 3 [42]. The primers used to 
amplify and sequence the gene and their location can be viewed in Appendix 2. Primers were 
ordered from the company TAG Copenhagen A/S [44] and all PCR reactions were done using 
Applied Biosystem 2720 Thermal Cycler. PCR program for CTLA-4 sequences and the 
microsatellite amplification was optimized using different PCR programs, annealing 
temperatures and Elongation time. All PCR products were separated on 2% agarose gel to 
verify correctly sized amplified products.  
 
 
CTLA-4 Promoter and exon 1 PCR amplification 
All PCR fragments containing the CTLA-4 promoter sequence and exon 1 were amplified 
with the forward and reverse primer, called primer-pair 1, shown in Table 1 and the product 
size from the Primers is 1943 base pairs long. 
 
Table 1. Primers for amplification of CTLA-4 promoter region and exon1. 
Forward 5’-GCC CGT ATT CCA CAG AGT GT-3’ 
Reverse 5’-TCT GAA ACC TGG GGA ATC TG-3’ 
 
The PCR reaction included, for one 50µl reaction, 1* AmpliTaq Gold buffer containing 1.5 
mM MgCl2. 0.2µM of forward and reverse primer, 0.2 mM dNTP and 2U AmpliTaq GoldTM 
Taq polymerase and 100ng of genomic DNA. The PCR program used included an initial 
denaturation step at 94ºC for 5 min followed by 40 cycles of amplification, denaturation at  94 
ºC for 40 seconds, annealing at 55 º in 40 seconds and extension at 72 ºC in 3 min, the 
program the contains a final extension step at 72 ºC in 5 min.  
 
To be able to sequence this product internal sequencing primers were designed (Table 2). The 
sequence product from these primers is 888 bp. 
 
Table 2. Sequencing primers for the CTLA-4 promoter and exon 1 region. 
Forward 5’- AAA GCT GTC ATG GGT CAA GG-3’ 
Reverse 5’- TTG GCT TCT GGC TTG GTT AT -3’ 
 
 
CTLA-4 exon 2 PCR amplification 
Primers used to amplify exon 2 were forward and reverse primer, called primer-par 2, found 
in Table 3. These primers give a product of 2315 bp. 
 
 
Table 3. Forward and reverse primer for amplification of CTLA-4 exon 2. 
Forward 5’-AGG CAT TGA CGA GGA GCT TA-3’  
Reverse 5’- CCA GGC TCA AGC AAA ATC TC-3’ 
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PCR amplification of CTLA-4 Microsatellites  
On the forward primer an M13 tail was added to be able to fluorescently mark the PCR 
product. The microsatellites were amplified with the forward and the reverse primer found in 
Table 4. Each PCR reaction was 12.5µl and contained 1* AmpliTaq Gold buffer containing 
1.5 mM MgCl2. 0.02 µM of forward primer, 0.2 µM TET and 0.2µM of reverse primer, 
0.2mM dNTP, 0.5U AmpliTaq GoldTM Taq polymerase and 12.5ng of genomic DNA.  
 
To amplify the DNA fragment a touch down program was used that included an initial 
denaturation step at 94ºC for 5 min followed by 14 cycles of 94º C for 30s. Annealing with 
touchdown from 61ºC- 47ºC 30s dropping one degree ºC each cycle, and finallyan extension 
step in 72ºC for 30s. After the 14 cycles a second cycle starts with 35 cycles of 94º C for 30s, 
the annealing with 52ºC 30s and then a extension step in 72ºC. The program is terminated 
with a final extension step at 72 ºC for 15 min. 
 
Table 4. The primers for amplification of the CTLA-4 microsatellite. On the forward primer 
an M13-tail of 19 nucleotides has been added. 
Forward 5 ‘- CAC GAC GTT GTA AAA CGA CAA TAA TGC CTG GGA ATG TGG-3’  
Reverse 5 ‘- ATG GTA ACA GGG TGC CTT CC-3 ‘ 
 
The length of the microsatellite found in the dog genome database was 257 bp. 
 
gtgaagaagggagagtggcggaagaggtggtggcggtggcaggggaagcccacagaagtt 
agcagcagggttgcctcagcctacagaggaaacgacctggtaccccctgctctgtggctt 
ccttcatttatcagcatccctccccctgataataatgcctgggaatgtggcagctggcac 
aatgatccagggttcagccactgtggctgataggggtacagggccaaggaaaatgtaggc 
agaggtttgtgaggtatgcattgaggggtaaggcaagattctatacttcagcctctaaaa 
tttcccttactactctttttaaattttatttatttatttatttatttatttatttattta 
tttattttttcccctactactctttatagttcctgtaattctatgataaccctagaatac 
cagaggtggaaggcaccctgttaccatcaaaccctccttactgtgtgtgagggaaaatga 
aggttacaggggatgcatgacttgcccccaaatcacatatttcatgggagggtcaggcct 
tcagtttgtcacatcagtgttctttctgctataggaaactcttgtccaataagaaaacgc 
cttttggagtttagctggaagatagccaagagattgaggggacagatgcggggagaggga 
 
Figure 5. Microsatellite TTTA and location of primers. 
 
 
M13-tail 
M13-tail is added 5’ on the forward primer witch is used for labelling of the PCR products. 
The fluorescently labelled universal M13 primer technique was developed to decrease the cost 
of labelling. M13-tails are available in different colours; the different dyes may be 6-carboxy-
fluorescine (FAM) or tetrachloro-6-carboxy-fluorescine TET, blue respectively green. [28]. 
 
 
MegaBace 
M13 labelled PCR products are then analyzed in a MegaBACE 1000 (Amersham 
Biosciences). The MegaBACE is a capillary instrument which separates the products in 
capillaries containing poly-acrylamide-gel. Samples are electro-kinetically injected and 
separated. Standard curve spans from 60bp to 400bp the PCR products containing 
microsatellites may therefore have a size between 80 bp and 350bp. The results are then 
viewed using a program called Genetic Profiler 2.2 (Amersham Biosciences).  
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DLA-DRB1 exon 2 PCR amplification 
PCR primers used, to amplify the DLA-DRB1 exon 2 sequences, were already designed [4]. 
Forward and reverse primers used are found in table 5. All PCR reactions to amplify DLA-
DRB1 exon 2 was 50µl reactions each containing 1* AmpliTaq Gold buffer, 1.5 mM MgCl2. 
0.1µM of forward and reverse primer, 0.1 mM dNTP, 1U AmpliTaq Gold TM Taq polymerase 
and 100ng of genomic DNA. 
 
The PCR program for amplification contained an initial denaturation step at 94º C in 5 min 
followed by 40 cycles of 94 ºC in 40 s 64 º in 40 s, 72 º C in 1 min, and then a conclusive 
extension step in 72 º in 5 min.  
 
Table 5. PCR primers used to amplify DLA-DRB1 sequence. The product from these primers 
is 269 bp. 
Forward 5’ –GAT CCC CCC GTC CCC ACA G-3’ 
Reverse 5’-TGT GTC ACA CAC CTC AGC ACC A-3’ 
 
 
PCR purification 
PCR purification was performed before sequencing and cloning using commercial kits. Kits 
for gel purification (E.Z.N.A.) and PCR purification kit (Quiagen) was used.  
 
 
Cloning of DLA-DRB1 PCR fragments 
All cloning was performed with modified commercial kit. (TOPO TA cloning kit, 
InvitrogenTM). Samples were cloned into TOPO TA plasmid vector and made on plates with 
ampicillin and X-gal following a modified protocol from the TOPO TA Cloning Kit [14]. The 
clones were purified with a QIAprep Spin Miniprep Kit (Quiagen). DNA sequencing was 
performed from at least three separate plasmid clones from each cloning experiment with the 
T7 forward primer and the M13 reverse primer. 
 
 
Plasmid PCR 
To control if the clones contained the DLA-DRB1 sequence some were tested in a plasmid 
PCR. Using colonies cultured in water and the same PCR program for the amplification of the 
DLA-DRB1 segment only with 20µl reactions instead of 50µl. PCR products was the analyzed 
on a 2% agarose gel. Positive clones were then sequenced. 
 
 
DNA Sequencing 
For PCR products a concentration of about 10ng/100bp is needed for sequencing. 
 
For plasmid DNA a concentration of 150ng/reaction was used. 
 
The purified PCR products were run in a 10µl sequence reaction together with 0.5µM of 
primer and 4µl of Sequencing Reagent Premix chemistry (DYEnamic TM ET Dye Terminator 
Cycle Sequencing Kit (MegaBACE, Amersham Biosciences)). The sequencing profile 
included 40 cycles of amplification (denaturation for 20s at 96°C, annealing at 50C° for 15s 
and extension for 1 min and 30s at 60°C). After the sequencing reaction the samples were 
precipitated using a modified Ethanol Precipitation Protocol (Amersham Biosciences) and 
finally diluted in 10µl loading Solution for MegaBACE TM 1000.  
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Analyzing sequences  
Sequences from CTLA-4, promoter region and exon 1, and DLA-DRB1, exon 2, were 
analyzed using Sequencher 3.1.1. 
 
 
Results & Discussion 
 
The primers denoted CTLA-4 primer-pair 1 amplified the sequence in the optimized PCR 
program. Because of the length of the amplified sequence; high PCR product concentrations 
were needed. I was unable to obtain this concentration; even after 40 cycles of amplification 
the concentrations was to low. Sequencing using the MegaBACE requires approximate 
concentrations of 10ng/100bp. Therefore, sequencing primers were designed for this matter 
but not even this resolved the problem. To avoid these problems, PCR products can be 
purified using the kit MiniEluteTM (Qiagen) which is supposed to give higher concentrations. 
If this doesn’t give sufficient concentrations new primers need to be designed to amplify 
shorter sequences. When the sequence is available, cases and controls can be compared to 
find SNPs. The promoter sequence can be analyzed in the database rVista 2.0 [43] to 
determine whether conserved regions have any mutations that could affect the gene 
expression or function.  
 
The second primer pair used to amplify CTLA-4 exon 2 did not amplify the sequence. I 
performed different approaches to solve this problem without obtaining successful results. I 
tried different annealing temperatures in the PCR, touch-down PCR, betaine PCR and 
genomic DNA from different breeds; Giant Schnauzer, Hovawart, Drever and Boxer, the 
latter is the breed from which the genomic nucleotide sequence present in the database was 
derived and thus used for primer design. The lack of successful PCR amplification may 
therefore be caused by sequencing artefacts of the sequence found in the database. The 
difficulties in amplification could also depend on the size of the sequence selected for 
amplification. To solve the problem, additional primers should be designed.  
 
Because of the sequencing problems with both primer pairs, I decided to perform a 
microsatellite approach. A microsatellite placed immediately upstream of exon 2 was 
examined with MegaBACE and genetic profiler. The results from Giant Schnauzer gave four 
different alleles for this marker. I also investigated cases and controls of Hovawart with this 
microsatellite but because of the close relationship between individuals in this breed the 
marker was not informative. There were four alleles present with one of these alleles 
represented in almost all the Hovawart individuals tested. Therefore, I preceded the study 
with only Giant Schnauzer because of their high allelic variability.  
 
Cases and controls from Giant Schnauzer were analyzed in a program called Conting version 
2.71. [35] 
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Table 6. List of the cases and the alleles analyzed with microsatellites and the program 
Conting 2.71 [35].  
Cases Allele 1 Allele 2 
2.45.48 312 312 
2.45.80 316 316 
2.45.99 312 312 
2.45.293 296 296 
2.45.289 312 312 
2.45.292 296 296 
2.45.164 296 296 
2.45.39 296 296 
2.45.250 312 316 
2.45.218 296 296 
2.45.298 312 312 
2.45.133 312 312 
2.45.32 296 296 
2.45.225 312 312 
2.45.26 296 296 
2.45.150 312 316 
2.45.206 296 296 
2.45.232 296 312 
 
 
Table 7. List of the controls and the alleles that were analyzed with microsatellites and the 
program Contig 2.71 [35].  
Controls Allele 1 Allele 2 
2.45.49 312 312 
2.45.68 296 296 
2.45.30 296 296 
2.45.297 312 316 
2.45.296 312 316 
2.45.285 296 296 
2.45.60 312 312 
2.45.295 312 312 
2.45.51 312 312 
2.45.290 312 324 
2.45.95 312 312 
2.45.288 296 296 
2.45.286 296 296 
2.45.23 296 312 
2.45.43 316 316 
2.45.17 312 312 
2.45.18 316 316 
2.45.27 296 296 
2.45.30 296 312 
2.45.54 312 312 
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After the program calculated a chi square for three degrees of freedom and the analysis gave a 
result of 1.96. For a Chi square to be significant for three degrees of freedom it should be 
greater than or equal to 7.82. The P-value produced was 0.58 and the distribution is 
statistically significant when the P-value is less than 0.05. The definition of P-value is the 
probability of obtaining a result as extreme as the observed one, if there is truly no effect [11]. 
The Chi square and P-values obtained in this analysis show no significance between the 
alleles. To obtain conclusive results additional animals needs to be analyzed. 
 
Future studies of the potential involvement of the CTLA-4 gene are to investigate whether the 
3’-UTR has mutations associated with CLT. In Hashimoto’s thyroiditis a mutation in the 3’-
UTR has been associated with the disease [5, 12, and 23].   
 
The cloning of exon 2 PCR products of DLA-DRB1 was performed using different approaches 
due to difficulties to exclusively isolate the correct exon 2 PCR product. In several cases, 
additional fragments were obtained. The nature of these fragments has not been evaluated. 
The PCR conditions were stringent according to already published procedures. However, the 
obtained results suggest that the PCR primers have the capacity to amplify additional products 
from other templates in the dog genome. Characterization by PCR of the isolated recombinant 
plasmids, however, allowed us to exclude clones that contained other sequences than DRB1. 
Another complication associated with cloning of the PCR products are artefacts due to errors 
introduced by Taq polymerase in the PCR product used in cloning. In order to avoid these 
artefacts, characterization of PCR products from multiple PCR reactions and at least three 
different clones are required to obtain conclusive results. The initial problems associated with 
false-positive clones and problems with the T7 forward primer used for nucleotide sequencing 
were solved after extensive experimentation. Allele investigation of the obtained DLA-DRB1 
sequences was performed in collaboration with Susanne Björnerfeldt. The complement of my 
clones to previous result was satisfying. My cloning results made it possible to remove eight 
wrongly characterized alleles and addition of one new allele to the study. All alleles currently 
identified in this study from Giant Schnauzer and Hovawart can be viewed in Appendix 3.  
 
The current characterization of the complexity of DLA-DRB1 allelic polymorphism in Giant 
Schnauzer and Hovawart has allowed us to conclude that these populations have at least 13 
and 6 different DRB1 alleles, respectively. An allele of DRB1 denoted #5 is suggested as a 
potential risk factor predisposing for CLT. Ongoing studies will evaluate this hypothesis with 
further sequencing of DRB1 alleles and a variety of statistical analysis. A study where 
susceptibility epitopes will be evaluated will also be performed based on the DRB1 sequences 
in these breeds. Certain DRB1 epitopes are known to be associated with the autoimmune 
disease, Rheumatoid arthritis [26]. Such alleles can be found in Hovawart and Giant 
Schnauzer. Their potential involvement as risk factors in CLT will be assessed.  
 
In future DRB1 studies of these populations aimed at defining individual MHC class II 
genotypes we will employ a high-throughput system developed by Kennedy and co-workers 
[19]. This new method has been developed to efficiently deduce the DLA-DRB1 genotype. 
This article describes a method that uses reference strand-mediated conformational analysis 
for a high-resolution characterization of the locus [19]. In addition to defining the MHC class 
II genotype in these CLT-affected populations, a genome-wide association mapping study 
will be performed using a SNP-based array platform with 20.000 SNPs. To perform this 
genome-wide association analysis, more CLT cases and healthy controls are required. A 
genome scan requires at least samples from 100 cases and 100 controls to obtain significant 
power in the study. Currently, we have collected a total of 157 samples, among these samples, 
36 are CLT-positive and 74 are CLT-negative [11].  
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DLA-DRB1*00101       CA CAT TTC TTG GAG GTG GCA AAG TCC GAG TGC TAT TTC ACC AAC GGG ACG GAG CGG GTG CGG TTC GTG GAA AGA         Appendix 1.  
 DLA-DRB1*00102       -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00201       -- --- --- --- --- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- -CG ---  
 DLA-DRB1*00202       -- --- --- --- --- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- -CG ---  
 DLA-DRB1*00301       -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00401       -- --- --- G-- T-C CA- TTT --- C-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00501       -- --- --- --- --- A-- TT- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00601       -- --- --- --- --- --- --- --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00701       -- --- --- --- --- --- --- --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00801       -- --- --- G-- A-- A-- TAT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- ATG ---  
 DLA-DRB1*00802       -- --- --- G-- A-- A-- TAT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- ATG ---  
 DLA-DRB1*00901       -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*010011      ** *** *** G-- T-C CA- TTT --- C-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*010012      ** *** *** G-- T-C CA- TTT --- C-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01101       -- --- --- G-- A-- A-- TTT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -CG ---  
 DLA-DRB1*01201       -- --- --- G-- AG- A-- TAT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --T C-- -CG ---  
 DLA-DRB1*01301       -- --- --- G-- T-C CA- TTT --- C-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01401       -- --- --- --- --- A-- TT- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01501       -- --- --- --- --- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -TG ---  
 DLA-DRB1*01502       -- --- --- --- --- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -TG ---  
 DLA-DRB1*01503       -- --- --- --- --- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -TG ---  
 DLA-DRB1*01601       -- --- --- --- --- --- --- --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01701       -- --- --- G-- A-- A-- TTT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --T C-- -CG ---  
 DLA-DRB1*01801       -- --- --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01901       -- --- --- G-- AG- A-- TAT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --T C-- -CG ---  
 DLA-DRB1*02001       -- --- --- --- A-- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- --G --- --- ---  
 DLA-DRB1*02101       -- --- --- G-- A-- A-- TTT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -CG ---  
 DLA-DRB1*02201       -- --- --- G-- T-C CA- TTT --- C-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02301       -- --- --- --- --- A-- TT- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02401       -- --- --- --- --- --- TT- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02501       -- --- --- --- --- --- TT- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- --G --- --- ---  
 DLA-DRB1*02601       -- --- --- --- --- A-- TT- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02701       -- --- --- G-- T-C CA- TTT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02801       -- --- --- --- --- --- --- --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02901       -- --- --- G-- A-- A-- TAT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- ATG ---  
 DLA-DRB1*03001       ** *** *** --- --- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -TG ---  
 DLA-DRB1*03101       -- --- --- --- A-- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- ATG ---  
 DLA-DRB1*03201       -- --- --- G-- T-C CA- TTT --- C-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03301       -- --- --- --- --- A-- TT- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- -TG ---  
 DLA-DRB1*03501       -- --- --- G-- A-- A-- TTT --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -CG ---  
 DLA-DRB1*03601       -- --- --- --- --- A-- TT- --- --- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03701       -- --- --- --- --- --- --- --- G-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03801       -- --- --- --- --- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- C-T C-- -TG ---  
 DLA-DRB1*03901       -- --- --- G-- T-C CA- TTT --- C-- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04001       -- --- --- --- A-- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- --G --- --- ---  
 DLA-DRB1*04101       -- --- --- --- --- A-- TT- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- ATG ---  
 DLA-DRB1*04201       -- --- --- --- --- A-- TT- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- -TG ---  
 DLA-DRB1*04301       -- --- --- --- --- A-- TT- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- -TG ---  
 DLA-DRB1*04401       -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --A --- --- ---  
 DLA-DRB1*04501       -- --- --- --- --- A-- TT- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04601       -- --- --- --- --- A-- TT- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04701       -- --- --- --- A-- A-- -T- --- -T- --- --- C-- --- --- --- --- --- --- --- --- --- -AT C-- ATG ---  
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 DLA-DRB1*00101      TAC ATC CAT AAC CGG GAG GAG TTC GTG CGC TTC GAC AGC GAC GTG GGG GAG TAC CGG GCG GTC ACG GAG CTC GGG  
 DLA-DRB1*00102      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*00201      G-- --- T-- --- --- --- --- A-- C-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00202      G-- --- T-- --- --- --- --- A-- C-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00301      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*00401      C-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00501      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00601      --- --- T-- --- --- --- --- -A- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00701      --- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00801      G-- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*00802      G-- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*00901      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*010011     --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*010012     --- --- --C --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01101      AG- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*01201      AG- --- T-- --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01301      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01401      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01501      G-- --- T-- --- --- --- --- CA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01502      G-- --- T-- --- --- --- --- CA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01503      G-- --- T-- --- --- --- --- CA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01601      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01701      AG- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01801      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01901      AG- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02001      G-- --- T-- --- --- --- --- -A- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02101      AG- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*02201      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02301      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02401      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02501      --- --- T-- --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02601      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02701      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02801      --- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02901      G-- --- T-- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*03001      G-- --- T-- --- --- --- --- CA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03101      G-- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*03201      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03301      G-- --- T-- --- --- --- --- CA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03501      AG- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*03601      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03701      --- --- T-- --- --- --- --- -A- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03801      G-- --- T-- --- --- --- --- CA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*03901      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04001      G-- --- T-- --- --- --- --- -A- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*04101      G-- --- T-- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*04201      G-- --- T-- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*04301      G-- --- T-- --- --- --- --- CA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04401      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
 DLA-DRB1*04501      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04601      --- --- --- --- --- --- --- AA- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04701      G-- --- T-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- --- --- --- --- ---  
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 DLA-DRB1*00101      CGG CCC GTC GCT GAG TCC TGG AAC GGG CAG AAG GAG ATC TTG GAG CAG GAG CGG GCA ACG GTG GAC ACC TAC TGC  
 DLA-DRB1*00102      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00201      --- --- A-- --- --- --- --- --- C-- --- --- --- --- --- --- --- AG- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00202      --- --- A-- --- --- --- --- --- C-- --- --- --- --- --- --- --- AG- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00301      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00401      --- --- -A- --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*00501      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- --- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00601      --- --- -A- --- --- -A- --- --- CC- --- --- --- C-- --- --- -G- -C- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00701      --- --- -A- --- --- -A- --- --- CC- --- --- --- C-- --- --- GG- -GC --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00801      --- -G- -A- --- --- -A- --- --- --- --- --- --- --- --- --- -G- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00802      --- -G- -A- --- --- -A- --- --- --- --- --- --- --- --- --- -G- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*00901      --- --- -A- --- --- --- --- --- C-- --- --- --- T-- --- --- -G- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*010011     --- --- --- --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*010012     --- --- --- --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*01101      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- AG- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*01201      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- AG- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*01301      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- --- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*01401      --- --- -A- --- --- -A- --- --- CC- --- --- --- C-- --- --- -G- -C- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*01501      --- --- -A- --- --- -A- --- --- --- --- --- --- C-- --- --- --- AG- --- --C GA- --- --- --G GTG ---  
 DLA-DRB1*01502      --- --- -A- --- --- -A- --- --- --- --- --- --- C-- --- --- --- AG- --- --C GA- --- --- --G GTG ---  
 DLA-DRB1*01503      --- --- -A- --- --- -A- --- --- --- --- --- --- C-- --- --- --- AG- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*01601      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- A-- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*01701      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- -C- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*01801      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- A-- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*01901      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- AG- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*02001      --- --- TCG --- --- --- --- --- C-- --- --- --- T-- --- --- --- AG- --- --C GA- --- --- --G GTG ---  
 DLA-DRB1*02101      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- AG- --- C-C G-- --- --- --- --- ---  
 DLA-DRB1*02201      --- --- -A- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*02301      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- --- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*02401      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- A-- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*02501      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- AG- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*02601      --- --- -A- --- --- -A- --- --- C-- --- --- --- C-- --- --- -G- A-- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*02701      --- -G- -A- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*02801      --- --- -A- --- --- -A- --- --- CC- --- --- --- C-- --- --- -G- -C- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*02901      --- -G- -A- --- --- --- --- --- --- --- --- --- --- --- --- -G- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*03001      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- AG- --- --C GA- --- --- --G GTG ---  
 DLA-DRB1*03101      --- -G- -A- --- --- --- --- --- --- --- --- --- C-- --- --- --- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*03201      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --G GTG ---  
 DLA-DRB1*03301      --- --- -A- --- --- -A- --- --- C-- --- --- --- C-- --- --- -G- AG- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*03501      --- -G- -A- --- --- --- --- --- C-- --- --- --- T-- --- --- --- AG- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*03601      --- -G- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- -G- A-- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*03701      --- --- -A- --- --- --- --- --- CC- --- --- --- C-- --- --- -G- -C- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*03801      --- --- -A- --- --- -A- --- --- --- --- --- --- C-- --- --- -G- AG- --- --C GA- --- --- --G GTG ---  
 DLA-DRB1*03901      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 DLA-DRB1*04001      --- --- TCG --- --- -A- --- --- --- --- --- --- --- --- --- --- AG- --- --C GA- --- --- --G GTG ---  
 DLA-DRB1*04101      --- -G- -A- --- --- --- --- --- --- --- --- --- C-- --- --- --- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*04201      --- --- -A- --- --- -A- --- --- --- --- --- --- C-- --- --- --- A-- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*04301      --- --- -A- --- --- -A- --- --- C-- --- --- --- C-- --- --- -G- AG- --- --C GA- --- --- --G GTG ---  
 DLA-DRB1*04401      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- AG- --- --C G-- --- --- --- --- ---  
 DLA-DRB1*04501      --- --- -A- --- --- --- --- --- --- --- --- --- C-- --- --- -G- A-- --- --C GA- --- --- --- --- ---  
 DLA-DRB1*04601      --- --- -A- --- --- --- --- --- C-- --- --- --- C-- --- --- --- --- --- --C G-- --- --- --- --- ---  
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 DLA-DRB1*04701      --- -G- -A- --- --- --- --- --- --- --- --- --- C-- --- --- -G- AG- --- --C G-- --- --- --- --- ---  
  
 
 
 DLA-DRB1*00101      AGA CAC AAC TAC GGG GTG ATT GAG AGC TTC ACG GTG CAG CGG CGA G    
 DLA-DRB1*00102      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00201      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*00202      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00301      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00401      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00501      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00601      --- --- --- --- --- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00701      --- --- --- --- --- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00801      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*00802      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*00901      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*010011     --- --- --- --- --- --- --- *** *** *** *** *** *** *** *** *    
 DLA-DRB1*010012     --- --- --- --- --- --- --- *** *** *** *** *** *** *** *** *    
 DLA-DRB1*01101      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01201      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01301      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01401      --- --- --- --- --- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01501      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01502      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*01503      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01601      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01701      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01801      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*01901      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02001      --- --- --- --- --- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02101      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02201      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02301      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02401      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02501      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02601      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02701      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02801      --- --- --- --- --- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*02901      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*03001      --- --- --- --- --- --- --- *** *** *** *** *** *** *** *** *    
 DLA-DRB1*03101      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*03201      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*03301      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*03501      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*03601      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*03701      --- --- --- --- --- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*03801      --- --- --- --- C-- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*03901      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*04001      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*04101      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*04201      --- --- --- --- --- --- --- --- --- --- G-- --- --- --- --- -    
 DLA-DRB1*04301      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*04401      --- --- --- --- C-- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*04501      --- --- --- --- --- --- GGC --- --- --- --- --- --- --- --- -    
 DLA-DRB1*04601      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -    
 DLA-DRB1*04701      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -   
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Appendix 2.  
 
The CTLA-4 gene and primers, the highlighted sequences mark the primers used in this study. 
 
Promoter sequence and exon 1 
Forward 5’-GCC CGT ATT CCA CAG AGT GT-3’ 
Reverse 5’-TCT GAA ACC TGG GGA ATC TG-3’ 
 
Sequencing primers 
Forward 5’- AAA GCT GTC ATG GGT CAA GG-3’ 
Reverse 5’- TTG GCT TCT GGC TTG GTT AT -3’ 
 
 
Exon 2 primers 
Forward 5’-AGG CAT TGA CGA GGA GCT TA-3’  
Reverse 5’- CCA GGC TCA AGC AAA ATC TC-3’ 
 
gcctgaacatacattttccagttttgtatcttcagtgccctctctgggatctggccctta 
gtaagatcccatgggttgcttttgcctgctaacatttcagctggatttgaaggcttatat 
aaggttggggggaggggtataaaaaagggcctcaggagaagctccctgaggagctgtcgt 
attaattaactgctggaggagaagaaggaggattggataagataatgggagaaaataggc 
attggaacaacatgagtaaagttgatgagatatgtaagaggtatgttggacaaaaagagg 
aagggggcatgtgaagaaatgctggaagccaggctaaaaagagaggcattaggcccgtat 
tccacagagtgtcctctactgtgctgagctatatggacagtgggaaatcataaagtgtgg 
gaataggcatgttgtaactgtctgtttgcctgtcagtctcctagaagtcccttaaggcat 
taactgcattttgtccagtcatctttcaatctaagtgcatatcccatatcactggcatat 
cacaggttctcaagaaatgtctctttcattattgaagtacatgaaaactcctccgtatta 
agcgaggtggtccccaatgtagtattctcttacagtatgaacactggtcctgttcacagt 
tttcataaatttaagaacttcagtcatatttaacctgagctcttggattttatgcttgaa 
aagttccctttagaaagaaaaacatgtctctcctcatatggaaggtttgaatctcttgga 
tcattttggctgactttttttggaccgtttccaactctattttgtctttgttaaggcttt 
taagaatacctgaattctttcctaatctgcaagccagaggcaaattcatttatttcccgt 
gatttgggtattttctctcaacaaaatgctaaatggagcttagagaagtaaactcttatt 
tgtaaacctgccagggatggtgaatgcagggcttttattaatgatgtctatggactaaag 
ctgtcatgggtcaaggactcagaccagcagcttagcagctttggagatgtgaatgaagta 
aattggctggttaaagatgcctagataattggacaaattgggacctaggaagactcctgc 
actccaggaaattctccaagtctccacttatcctcaaagtgaacaagaagcttcagtttc 
aaattgagtgcattttccatccatggattggcttgttttgttcagttttactttgagtgt 
ttgaggttatcttttcgacgtaacagctaaacccacggcttcctttctcgtaaaaccaaa 
acaaaaaggctttctattcaggtgccttctgtgtgtgcacatgtatagtacatacctggg 
atcaaagccagctatataaagtccttgattctgtgtgggttcaaacacatttcaaagctt 
 
 
CAGGATCCTGAAAGGTTTCACTCTGCTTCCTGAAGACCTGAACACTGCTCCATAAAGCCA 
TGGCTGGCTTTGGATTCCGGAGGCATGGGGCTCAGCCGGACCTGGCTTCTAGGACCTGGC 
CCTGCACTGCTCTGTTTTCTCTTCTCTTTATCCCCGTCTTCTCCAAAG 
 
gtgagtgaggcttttggaggatgaaggtggaggaggtgtttctcccacctgtgtttcatt 
tctttcagcagtcaaggacagtgatttataaccaagccagaagccaaaggtaagactcca 
gtctcctagctcggatagctctgtattctagggcaggcggggaacagctggcagcagcaa 
ataagcagagatacatctcatagtggagcaccaggcattgacgaggagcttaatgaatat 
atctgagttggtttgggagatgagcaatttcagacatttctgtaagattggaagaaaata 
ctgtaaggttaagtgacttaagagaggaagggtatccgtagcccttcacgtgtttaagtt 
tggaatcagggtgaactcaggaatttcctttttgcaaaacattgatttaagtgaatcatt 
taagtttctttcctacccaatttaagattttaagatcttctaattcacttttataaatga 
atcgcttgtttaaaatttaagccttctttacccggttcaaagttttaaggtcctcagtca 
attctataaaatagttggctaattacttaaaaagaaaagcagtttgaaattgtaaaacaa 
acaaacaaacaaaagaaataaggggagaaagaaagaaaaagaaagccatcagtctgtttg 
gcgtaggacacttaattgccatctaacctatctgtggacttcagatgcagattccccagg 
tttcagatgaaataaaactctttagaggttgatgccaggtttgctataggacataaatga 
tgagcattctcactgaatttcaacctttacctctctctagaccatctccgttaagaaacc 
atgtagtttatatgaaatatcttagctgctcaaaagatatttgatgattaaattattacc 
agataagaaatattcatatacactttcctattctatatgttttgagcatgtaaagattaa 
atactcttagaagtaattatctttattttgtagaaaatttatctcaacctgtaacttagt 
ttctcccattgaaaaatgagtgtgaccagatttagtggtgataactgggaaactgcctga 
ggggaggacaggatacttgggtcttcaggcttagcatcaatacaataaagactattgagt 
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gctcttatgggcaggttctaatggaggctcccaggagtttataagccaaaggcagatgtt 
gcaagaggtgtaattagtgcacaaaaaagtttattactttacttgattaaatactgcaat 
ggagttataacagtgtgaagaatgctcagaggatgctcaaaggatcctctaatagacagg 
gatgatatttggggaaaagactgttacctatccagccagggctgctggattaacactagc 
aatggctgctaccgtactattctctcttccaaggacagatgttgtccagtgcaggtactt 
gggagaaaggactagtgatagagtgatttctatagagtgatttatacactctagaaactc 
agactggagtgataggttgggattggatcatggaggacataaaaaaacactttatttgtt 
tttgcaatcaatggtatgtaaagcatcaaagggtttgagcagaatgagtgacatggttca 
tccgagttttgagtgtcactgtgtgcttgactagagaggggccaggttagttacaggaag 
gtaacttgacacgaggccatcattttttagatgacacgagcctttttgaatggagagctg 
gcctcctttgtcttgtaaaagccagaaggagaaagaacaaaggagtatgaaggtgttcga 
gtgaagaagggagagtggcggaagaggtggtggcggtggcaggggaagcccacagaagtt 
agcagcagggttgcctcagcctacagaggaaacgacctggtaccccctgctctgtggctt 
ccttcatttatcagcatccctccccctgataataatgcctgggaatgtggcagctggcac 
aatgatccagggttcagccactgtggctgataggggtacagggccaaggaaaatgtaggc 
agaggtttgtgaggtatgcattgaggggtaaggcaagattctatacttcagcctctaaaa 
tttcccttactactctttttaaattttatttatttatttatttatttatttatttattta 
tttattttttcccctactactctttatagttcctgtaattctatgataaccctagaatac 
cagaggtggaaggcaccctgttaccatcaaaccctccttactgtgtgtgagggaaaatga 
aggttacaggggatgcatgacttgcccccaaatcacatatttcatgggagggtcaggcct 
tcagtttgtcacatcagtgttctttctgctataggaaactcttgtccaataagaaaacgc 
cttttggagtttagctggaagatagccaagagattgaggggacagatgcggggagaggga 
aaggatgaggagtgcttgttgaagggagagaagcgctaaaggtgaagctggagggtaccc 
atcaaagatgaacttctgctagctggagattttgcttgagcctggttgtgggtgatcatg 
aatttgctgagttccctctaattttcctttattag 
 
GGATGCATGTGGCTCAGCCTGCAGTGGTTCTGGCCAGCAGCCGGGGTGTTGCTAGCTTCG 
TGTGTGAATATGGGTCTTCAGGCAACGCAGCCGAGGTCCGGGTGACAGTGCTGCGGCAGG 
CTGGCAGCCAGATGACTGAAGTCTGTGCCGCGACATACACAGTGGAGGATGAGTTGGCCT 
TCCTGGATGATTCTACCTGCACCGGCACCTCCAGTGGAAACAAAGTGAACCTCACCATCC 
AAGGGTTGAGGGCCATGGACACGGGGCTCTACATCTGCAAGGTGGAGCTCATGTACCCAC 
CACCCTACTATGTAGGCATGGGAAATGGAACCCAGATTTATGTCATCG 
 
gtgagcaaaaccatatcactaagctgaccattttgctttgctgtcctctttgcatgaata 
cagttttgttccttcaggtggttcatttttaggattatggaaattctttttaagaattct 
ttgccataccacatatagtctggttaatatgggtgtcaacccaaacagcattctgactaa 
aaataaaatggtttggggatagtgttttttctactagaggttggggccctcattctggaa 
tgataatcatcgtgaagtttatcaaggccttggggcaattgataggacattcctggggaa 
gtgactcccattagacagacttacctgtgaactagcaatactatttaaaggtggacacca 
aggttggaagctcttctagaacctcttccttttctcaccaatggggacggggagtagggc 
cctaaagtttaaagagtgtttcaaggaacttctgctttgttttccgtcacag 
 
ATCCTGAACCTTGCCCAGATTCTGACTTCCTCCTCTGGATCCTTGCAGCAGTCAGTTCGG 
GCTTGTTTTTTTATAGCTTTCTTATCACAGCTGTTTCTTTGAGCAAAATG 
 
gtgagtgcagtgctgacaacataccactttgggtggggatgccttcagtgatagcgactg 
accaaatgacgctgttgagttcagttttcttgagatgaagcaataaatgaagaacagtgg 
taaaggaaggacagtggtaaagaacgcactagaacccttggcattggcctttgaggtttc 
aggatgactaacattttagatgagtgtgtttgacattgaatgtttgtgtgcttctgaaca 
gggtttcagtttgagtaaccatttgaataacacagggcagctgttttgttctttgtcttc 
aagacaattgtacctaataactctgaaacataagattaggttgggcaaaatgctgctata 
gaagacctcctggatggattttattctcccccttaacatccctctacttcccctggaagc 
catctcttggtgctaccctgcttgtgccaccattatcaaagctatagttgtccacacaac 
accaggccggggcttcctgttatccagtctgctcaaatgggaagtcttgctttcccctcc 
agcccagtttttatttatttgcagttgcttgtggaagagatgtaggtatggagttaggga 
tcctgtcaggctttctttctgatggtccctttcaaccgcctctgcctatggttgtctttt 
tcaccacaaactctccttccttgcctctctcctcttcctccacctcccctctcccccaac 
tcaattccaagatcctctgctcaactgttctattgctgtagattcttcctacatttgcta 
aaaattgtcacaaagaacagtagactagaatctcaatttactgaggtgataaaaattggg 
aactaaggcagacagacaaaaagtaataaagagtataggaggagtggagatgagaaatac 
agctctagaacagaataactgaagtttattatcttaccaagctcttctcctcacagataa 
gatgtagtcatttaccatcgatattttgggtgttctttctaaagctttctcaaagtctct 
tgcagcagtgaaaatgattactattttccatcaatagcacagagtgatttatctaaagtg 
aattataaaagctaaatcaagaaaatctcctggggcttataattctgtacatgtgcattc 
atttttttccaacggagtggggaccaatatttgttgagtcctattatagctagagacagc 
ttctgtatttctcaataataattactgcttctttttgtgtttggcag 
 
CTAAAGAAAAGAAGCCCTCTTACCACAGGGGTCTATGTGAAAATGCCCCCAACTGAGCCA 
GAATGTGAAAAGCAATTTCAGCCTTATTTTATTCCCATCAATTGAGAGATCATTATGAAG 
AAGAAAGAATATTTTCCAATTTCCAGGAGCTGAGGCAATTCTAACTTTGTGCTATCCAGC 
TATGTGTACTTGTTTGTATATTTTGGGGGGGGTTTCATCTCTCTTTAATATAAAGCTGGA 
TGCAGAACCCAAATGAAGTGTACTACAAATTCAAAGCAAAGGTGCAAGAAAACAGAGCCA 
GGATGTTTCTGTCACATCAGATCCAATTTTCATAAAAGTATCACTTGGGAGCAATATGGG 
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GATGCAGCATTAGGACATGCGCTCTAGGATATAGGTTAGGGAGTGGTGCGGTCCAAAGAA 
AGCAAAGGAGAGAGAGTCAGGGAGAGGATGATATTGTACACACTTTGTATTTACATGTGA 
GAAGTTTATAGCTGAAGTGACGTTTTCAAGTTAAATTTTTGTGCTATGTTATTTTTCATA 
AATGTAAAATCACGTGAAGACTTTAAAAATACTCACATGGCTATATTTTAGCCAGTGATT 
CCAAAGGTTGTATTGTACCAATATATATTTTTTTATCTGATAGTATTATGCATGGGGGCC 
ACATGTGCTTTTGTGTATTTGTTGATGGTTTCAATATAAACACTATATGGCAGTGTCTTC 
CCACCAGGGGCTCAGGGGAAGTTTTATGGAGGGATTCAGGACACTAATACGCCAGGTAAA 
ATACAAGGTCACTTGGTAACTGGCTTGGAAACTGGATGAGGTCATAGTTGATTCTTGTAG 
ATGTGTTGGGCTAAATTGGTGTTGACATGTGCTTTGGGCTTTTATGTTAGCTCCTTTCAA 
AGATTTGTAAGGGAGTCAAAACTGGTATATCTGATTTAACTCCATAGAACACCATCGTCA 
AGTAAACGGCTCATTCCAGGAGTCTTGGAGGTATGAACTTCAAGGAAGCTCTAGTTTCAC 
AAGGGCCCCAATTCCTTGCTCATGGTTAATGCCATGGGCAGAAAACAGCAGCAGGTGGCA 
GAACAGGGTGATGAAGGTTTCCGAAAACAAACACTGTTGGTGTTTTTTTAACTCACTATT 
TTCTGTGAAAATGCAACAACATGTATAATATTTTTAATTAAATAAAAATCTGTGGTGGTC 
ATT 
 
ttccagagttgttgttatcttccttgtatttgaatattgtctttgaggttgcttttaatg 
gattcatccggcagttggtggagtctccattattattaatactgggaacaaattgacaaa 
aaggcaaataatgcttcatgggtcagctgccaccagccattacctgcaagccatttttgg 
aaggaactgaactcctcctctgtccttttgtttcttcacaactatttgaaatataaagca 
ggtttactgcagataacagcagaccttcagaagtcacagagcattctttctagcacaaat 
tcttcatctcctctttcttgcctacagatttctcagctcaactcctgcagttgccatggc 
aactcctgtgttgtcaatcacgttcctagcagccatttgatctgcttccatggtaaaagg 
agctttcccttacggcttctcaatggactatttcacacatgggggagaaaaatataccca 
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